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Abstract : Glutathione S-transferase （GST） is a major phase II drug-metabolizing 
enzyme.  Several isoforms of human GST as well as different GST genetic poly-
morphisms are known, but limited data exists concerning the relationship between 
GST polymorphisms and GST activity using 1-chloro-2,4-dinitrobenzene in human 
liver.  To resolve this query, we analyzed the genetic polymorphisms of four 
main GST isoforms ［GST mu 1 （GSTM1）, GST theta 1 （GSTT1）, GST alpha 1 
（GSTA1）, GST pi 1 （GSTP1）］ and measured hepatic GST activity isolated from 
the same patients.  We found that GSTM1 null individuals have signicantly lower 
（P＝ 0.0082） GST activity compared with GSTM1 positive individuals.  No signi-
cant changes in GST activity were observed in individuals with GSTT1, GSTA1, 
and GSTP1 genotypes.  Interestingly, the levels of GST activity exhibited were 
similar when compared with GSTA1＊A/＊A and GSTA1＊A/＊B, and GSTP1＊A/＊A 
and GSTP1＊A/＊B, respectively, if the genotype was GSTM1 null.  Therefore, the 
genotypes of GSTA1＊A/＊B and GSTP1＊A/＊B individuals do not signicantly affect 
the level of hepatic GST activity.  An examination of the correlation between GST 
mRNA expression and GST activity subsequently revealed a signicant correlation 
between GSTM1 mRNA levels and GST activity （r＝ 0.626, P＝ 0.007）.  These 
data are expected to facilitate research on the prediction of efcacy and safety of 
GSTM1 null-mediated drug metabolism and may establish whether genetic poly-
morphisms of the GST gene, specically GSTM1, can act as a biomarker.
Key words : glutathione S-transferase （GST）, gene polymorphisms, human liver, non-
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Introduction
　Glutathione S-transferase （GST） consists of multiple gene products that catalyze the 
conjugation of a wide variety of electrophilic drugs and chemicals.  Cytosolic GST isozymes 
comprise seven different isoforms ; alpha （A）, mu （M）, omega （O）, pi （P）, sigma （S）, theta 
（T） and zeta （Z）1）.  The genetic polymorphisms of GSTM, GSTT, GSTA and GSTP influence 
Original
1）Department of Pharmacotherapeutics, Division of Clinical Pharmacy, Showa University School of Pharmacy, 1—5-8 
Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan.
2）Department of Surgery, Division of General and Gastroenterological Surgery, Showa University School of Medicine.
＊ To whom corresponding should be addressed.
Tatsuhiro FUJIMIYA, et al114
the efficacy and safety of anti-cancer drugs, such as oxaliplatin, and affect cancer risk 2-4）.
　Previous studies of the genetic polymorphisms associated with GST isoforms have established 
that the genetic differences in GSTM1, GSTT1, GSTA1 and GSTP1 decrease GST activity1, 2）. 
GSTM1 null （gene deletion）5）, GSTT1 null （gene deletion）6）, GSTA1＊B （-567T＞G＋-69C＞T 
＋-52G＞A）7）, and GSTP1＊B （exon 5, 313A＞G）8） are the major polymorphisms that 
affect GST activity.  Zhou et al have reported that GSTM1 null ［formally known as GST-µ 
（negative）］ decreases GST activity when compared with GST-µ （positive）9）.  On the other 
hand, Arakawa et al have recently revealed that the GSTM1 null genotype does not alter GST 
activity 10）.  GST plays an important role in the detoxification of many electrophilic compounds 
with reduced glutathione in the liver.  Unfortunately, there is no reliable data on the relationship 
between GST variants and GST activity using 1-chloro-2,4-dinitrobenzene （CDNB） as a substrate 
in the human liver.
　In the present study, we focused on four GST isoforms （GSTM1, T1, A1 and P1） and 




　Biopsy specimens of normal human liver （noncancerous liver tissues） were obtained from 
18 Japanese hepatectomized patients （12 men, six women） with non-viral liver carcinoma 
（hepatocellular carcinoma, three patients ; intrahepatic cholangiocarcinoma, six patients ; metastatic 
liver cancer from colorectum and/or gastric cancer, nine patients） at Showa University Hospital. 
The liver specimens were numbered anonymously.  Written informed consent was obtained from 
all patients before the operation.  This study was conducted in accordance with the Declaration 
of Helsinki and its amendments and was approved by Human Genome Ethics Committee, 
Showa University.  Genomic DNA and total RNA were isolated from 18 individual liver samples 
but because insufficient cytosolic material was obtained in one specimen a total of 17 specimens 
were used.
Genotyping
　Genomic DNA was extracted from liver tissue using a NucleoSpinⓇ Tissue Kit （Macherey-
Nagel GmbH & Co. KG, Düren, Germany）.  Genotyping of GSTM1 and GSTT1 null 
individuals was performed using multiplex polymerase chain reaction （PCR）11）.  GSTA1＊
B （promoter region, -567T＞G＋-69C＞T＋-52G＞A） was detected using the primers as 
described by Coles et al 7）.  GSTP1＊B （exon 5, 313A＞G） was detected using the primers （5’- 
tccccagtgactgtgtgttg-3’ and 5’-gaagcccctttctttgttca-3’） designed by the Primer3 output program 
（http://bioinfo.ut.ee/primer3-0.4.0/）.  GSTA1＊B and GSTP1＊B were identified by direct sequence 
methods as described by Toda et al 12）.  PCR conditions and methods for the analysis of the 
GST genotype were performed as described by Kashiwabara et al 13） with some modification. 
The PCR mixture contained 1.0 to 2.5 U of AmpliTaqⓇ Gold DNA polymerase （Life 
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Technologies Japan Co., Ltd., Tokyo, Japan） and 150 to 300 ng genomic DNA.  The annealing 
temperatures ranged from 53℃ to 64℃.  Direct sequences were performed by BigDyeⓇ 
Terminator methods using BigDyeⓇ Terminator v3.1 Cycle Sequencing Kit （Life Technologies 
Japan Co., Ltd.）.  Reaction products were purified and then dried under vacuum.  All samples 
were resuspended with 25 µl of Hi-DiTM formamide （Life Technologies Japan Co., Ltd.） and 
analyzed on an ABI310 or ABI3100 Genetic Analyzer （Life Technologies Japan Co., Ltd.）.
Total RNA Isolation and Real-Time PCR
　Total RNA was isolated from liver tissues using the acid guanidinium thiocyanate-phenol-
chloroform extraction method14）.  Total RNA yield, purity and integrity were determined by the 
A260 /A280 absorbance ratio （＞1.6） and confirmed by examination of the RNA by electrophoresis 
on 1.2％ agarose/formamide gels.  Reverse transcription was performed using a TaKaRa RNA 
LA PCRTM Kit （AMV） Ver.1.1 （TaKaRa Bio Co., Ltd., Shiga, Japan）.  Real-time PCR was 
performed on an Eppendorf MastercyclerⓇ RealPlex2 （Eppendorf Japan Co., Ltd., Tokyo, 
Japan） using the TaqManⓇ Gene Expression Assay （Life Technologies Japan Co., Ltd.） for 
GSTM1 （Hs01683722_gH）, GSTT1 （Hs00184475_m1）, GSTA1 （Hs00275575_m1） and GSTP1 
（Hs02512067_s1）, and the TaqManⓇ Gene Expression Master Mix （Life Technologies Japan Co., 
Ltd.）.  Constitutively expressed human glyceraldehyde-3-phosphate dehydrogenase （GAPDH） 
（Hs00266705_g1） was used as an internal control for normalization.
Cytosol Extraction
　Liver tissues were homogenized with five volumes of 1.15％ KCl solution using a Potter-
Elvehjem homogenizer.  The hepatic cell cytosol was isolated by differential centrifugation and 
the cytosolic samples were immediately stored at -80℃.  Protein concentration was estimated by 
the method of Lowry et al 15） using bovine serum albumin as a standard.
GST Activity Measurement and Chemicals
　1-Chloro-2,4-dinitrobenzene （CDNB） was purchased from Sigma-Aldrich Co. Ltd. （Tokyo, 
Japan）.  GST activity was measured by the method of Habig et al 16） using CDNB as a 
substrate.  The final concentration of CDNB in a reaction mixture was 1 mM.  A unit of GST 
activity was expressed as µmol/mg protein/min.
Statistical Analysis
　Primary analysis was performed by Mann-Whitney U test for GST activity categorized 
into GST genotypes.  P values were calculated for two-sided tests of primary analysis, with 
Bonferroni correction P＜ 0.0083 considered statistically significant.  As a secondary analysis, 
Spearman’s rank correlation coefficient was used, and the relationship between mRNA expression 
and GST activity was evaluated.  Data were analyzed with SPSS Statistics Version 23.0 （IBM 
Japan, Co., Ltd., Tokyo, Japan）.
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Results and discussion
　Initially, we analyzed the genetic variants associated with different GST isoforms.  The 
genotype frequencies of GSTM1, GSTT1, GSTA1 and GSTP1 were determined and the 
frequencies of GSTM1 null, GSTT1 null, GSTA1＊A/＊B and GSTP1＊A/＊B genotypes were 77.8％, 
33.3％, 22.2％ and 38.9％, respectively （Table 1）.  The data was compared with published 
data 17, 18） and the Japanese Single Nucleotide Polymorphisms （JSNP） database （http://snp.ims.
u-tokyo.ac.jp/index.html） and we observed a higher frequency of GSTM1 null genotype in this 
study （77.8％） than in Munaka et al （49.3％）17）.  These data suggest that GSTM1 null may be a 
useful biomarker in patients with non-viral liver carcinoma.
　Fig. 1 shows the relationships between GST activity and GST genotypes ［GSTM1 （A）, 
GSTT1 （B）, GSTA1 （C）, and GSTP1 （D）］.  GST activity is significantly decreased in the 
GSTM1 null genotype in comparison with GSTM1 positive （Fig. 1A, P＝0.0082）.  This 
observation agrees with the findings of Seidegård et al 5）.  The GSTT1 null, GSTA1＊B, and 
GSTP1＊B genotypes have been observed previously to affect GST activity 6-8）.  We did not 
observe any statistically significant difference between GST activity and genotypes （Fig. 1B, C, 
D）, indicating that liver GST activity is affected mainly by GSTM1 variant.
　On the basis of these findings, we investigated whether the GSTM1 null genotype affects GST 
activity when the sample has the GSTA1＊A/＊A and GSTA1＊A/＊B or GSTP1＊A/＊A and GSTP1
Table 1.　 Frequencies of GST genotypes in Japanese 
patients with non-viral liver carcinoma
GST Genotypes
Number of patients and frequency
n ％
GSTM1




　Null  6 （33.3）
GSTA1
　＊A/＊A 14 （77.8）
　＊A/＊B  4 （22.2）
GSTP1
　＊A/＊A 11 （61.1）
　＊A/＊B  7 （38.9）
GSTA1＊A and GSTP1＊A are wild-type genotypes. 
GSTA1＊B and GSTP1＊B have polymorphisms of the 
GST promoter region （-567T＞G＋-69C＞T＋-52G＞A） 
and Ile105Val, respectively. The number in parentheses 
indicates genotype frequencies ; n is the number of 
patients.
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＊A/＊B genotypes.  GSTA1 and GSTM1 are major GST isoforms and are apparently expressed 
in human liver 19, 20）.  There were no statistically significant differences in GST activity between 
GSTA1＊A/＊A and GSTA1＊A/＊B or GSTP1＊A/＊A and GSTP1＊A/＊B （Fig. 1E, F）.  Similar 
results have been reported by Zhou et al in patients with hepatitis B virus （HBV） infection 9）. 
Fig. 1.  Relationship between GST activity and four GST isoform genotypes 
（GSTM1, GSTT1, GSTP1, GSTA1 ; A-D） in human liver （n＝
17）. Panels E and F show the relationship between GST activity and 
GSTA1 （E, ＊A/＊A and ＊A/＊B） or GSTP1 （F, ＊A/＊A and ＊A/ 
＊B） genotypes carried with GSTM1 null genotype （n＝14）. The 
horizontal bar denotes the median. The boxes represent the distribution 
of 25％ to 75％ and the whiskers show the lowest and highest. GST 
activity values were analyzed by the Mann-Whitney U test （＊＊P＜
0.01）; n is the number of patients. 1-Chloro-2,4-dinitrobenzene was used 
to measure GST activity.
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Although the patients in our study had no HBV infection, we concluded that GSTM1 null is 
a major genotype affecting GST activity when using CDNB as substrate in human liver.  In 
addition, the GSTM1 null gene may be useful as a biomarker for the prediction of low GST 
activity.
　Recently, Arakawa et al reported that the GSTM1 null genotype does not affect GST activity 
when using CDNB as a substrate 10）.  Their results suggest that GSTA1 and GSTP1 may affect 
GST activity.  We investigated and compared GST activity between GST genotypes including 
GSTA1＊B and GSTP1＊B because CDNB is a general substrate used to detect the total catalytic 
activity of GSTM1, GSTA1 and GSTP1 21）. However, we did not observe any differences in 
activity among the GST isoforms, which indicates that GSTM1 null genotype has a critical role 
in GST expression and in the maintenance of GST activity in human liver.
　The correlation between GST mRNA expression and GST activity is shown in Fig. 2.  The 
Spearman’s rank correlation coefficients between GSTM1, GSTT1, GSTA1 and GSTP1 mRNA 
levels and GST activity exhibited r＝ 0.626 （P＝ 0.007）, r＝ 0.187 （P＝ 0.473）, r＝-0.167 （P＝
0.523）, and r＝-0.172 （P＝ 0.510） in GSTM1, GSTT1, GSTA1 and GSTP1, respectively.  Thus, 
we observed a significant correlation between GSTM1 mRNA expression and GST activity.
　GSTM1 and GSTA1 mRNAs are expressed predominantly in the liver 22）.  Therefore, it is 
possible that GSTA1 affects GST activity but we did not observe a decrease in GST activity 
in the GSTA1＊A/＊B genotype （Fig. 1C, E）.  In this respect, Arakawa et al showed that GST 
activity is apparently maintained with GSTM1 null genotype when compared with GSTM1 
positive genotype10）.  In addition, the GSTA1＊B genotype has been shown to result in decreased 
protein expression and GST activity because of decreased activation of the proximal promoters 
of GSTA1 in HepG2 cells 7, 23, 24）.  The aryl hydrocarbon receptor （AhR） regulates the expression 
of GSTA1 and GSTA2 mRNAs 25, 26）, therefore we investigated the relationship between the 
expression of AhR mRNA and GSTA1 mRNA.  There is no significant difference between the 
expression levels of these genes （r＝ 0.195, data not shown）, which suggests that AhR does not 
regulate GSTA1 mRNA expression.
　Moscow et al and Nishimura and Naito have reported that GSTP1 mRNA is expressed at a 
low level in the liver in comparison with other tissues 22, 27）.  In the present study, we observed 
that GSTP1 mRNA is expressed in human liver.  GSTP1 mRNA expression is significantly 
induced by the presence of the GSTP1 Val105 variant allele 28）.  Therefore, it is apparent that 
GSTP1 genotypes affect GST activity.  Although it has been reported that the GSTA1＊B as 
well as the GSTP1＊B genotypes could significantly affect GST activity 8, 24）, we observed that 
GSTA1＊B has little effect on GST activity, indicating that GSTM1 genotypes may be largely 
responsible for GST activity.
　In conclusion, we investigated the simultaneous analysis of GST genotypes including GSTM1, 
GSTT1, GSTA1 and GSTP1 and liver GST activity in Japanese patients with non-viral liver 
tumors.  Although we obtained a limited number of patient specimens, we identified that the 
GSTM1 positive or GSTM1 null genotypes are responsible for GST activity using CDNB as 
a substrate.  A single GST substrate, CDNB, was used in this study because this compound 
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is a common substrate for measurement and evaluation of the enzymatic activities of GSTM1, 
GSTA1 and GSTP1 in human liver 21）.  A number of factors are associated with the regulation 
of GST activity and inter-individual differences have been reported.  The results of this study 
will facilitate the prediction of the efficacy and safety of GST-mediated drug metabolism 
including platinum-containing anti-cancer agents such as cisplatin and oxaliplatin.  This study 
indicated that genetic polymorphisms of the GST gene can act as a biomarker, however studies 
with a greater number of participants are necessary to clarify the relationship between the 
genotype of GST isoforms and GST activity.
Fig. 2.  The correlation between the expression of GST mRNA level and GST 
activity （n＝ 17）. The mRNA was normalized using glyceraldehyde-
3-phosphate dehydrogenase （GAPDH） as an internal control. The 
expression of mRNA （n＝ 18） in GSTM1 positive, GSTM1 null, GSTT1 
positive, GSTT1 null, GSTA1＊A/＊A, GSTA1＊A/＊B, GSTP1＊A/＊A 
and GSTP1＊A/＊B was 0.970 ± 0.073, 4.91 × 10-6 ± 1.84 × 10-5, 0.355 ±  
0.212, 2.89 × 10-4 ± 5.98 × 10-4, 0.645 ± 0.323, 0.348 ± 0.226, 0.400 ± 0.256 
and 0.327 ± 0.171, respectively. Closed circle, wild-type ; open circle, 
null or variant. The correlations were analyzed by the Spearman’s 
rank correlation coefficient （＊＊P＜0.01）. The correlation between 
GSTM1 mRNA level and GST activity was significant （P＝0.007）. No 
statistically significant difference was observed in GSTT1, GSTA1 and 
GSTP1 mRNAs with GST activity. GAPDH, glyceraldehyde-3-phosphate 
dehydrogenase ; GST, glutathione S-transferase ; r, rank correlation 
coefficient.
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